IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 401 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 1.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $164,568,000 | +50.7% | 2,027,449 | +0.4% | 0.20% | +31.4% |
| Q4 2018 | $109,207,000 | +2.4% | 2,020,126 | -2.3% | 0.16% | +25.8% |
| Q3 2018 | $106,646,000 | -12.7% | 2,067,600 | -29.5% | 0.12% | -15.1% |
| Q2 2018 | $122,179,000 | -3.6% | 2,932,050 | +2.0% | 0.15% | -7.6% |
| Q1 2018 | $126,733,000 | -6.3% | 2,875,025 | +6.9% | 0.16% | -3.1% |
| Q4 2017 | $135,306,000 | -1.5% | 2,689,981 | -0.7% | 0.16% | -3.6% |
| Q3 2017 | $137,316,000 | -1.2% | 2,708,407 | -0.9% | 0.17% | -1.7% |
| Q2 2017 | $139,054,000 | +27.0% | 2,733,518 | +0.4% | 0.17% | +29.3% |
| Q1 2017 | $109,469,000 | -16.0% | 2,723,100 | -0.0% | 0.13% | -19.4% |
| Q4 2016 | $130,266,000 | +62.1% | 2,723,506 | +24.2% | 0.16% | +63.4% |
| Q3 2016 | $80,374,000 | +82.9% | 2,193,626 | +16.3% | 0.10% | +74.1% |
| Q2 2016 | $43,936,000 | -25.1% | 1,886,451 | +30.2% | 0.06% | -25.6% |
| Q1 2016 | $58,693,000 | -62.7% | 1,449,191 | -43.0% | 0.08% | -22.0% |
| Q4 2015 | $157,342,000 | – | 2,540,642 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |